abstract: DNA methyltransferases-- @entity4 , @entity2 , and @entity3 --produce methylation patterns that dynamically regulate chromatin remodeling and gene expression. The vertebrate retina provides an ideal model to elucidate molecular control of neurogenesis as all neuronal cell types and M  ller glia are generated in a conserved order from common pools of progenitor cells. As a prelude to exploring epigenetic regulation of @entity0 retinal development, we investigated the expression of @entity4 , @entity2 , and @entity3 in the @entity1 retina from embryonic day (E) 10.5 to 10 months of age. High levels of transcripts for all three Dnmt genes were observed in early stages of retinal differentiation, with significantly reduced expression after birth. Although @entity4 protein is abundant in retinal progenitors at E10.5, it becomes restricted to postmitotic cells by E15.5. Most cells in the postnatal retina show nuclear immunostaining of @entity4 ; however, the photoreceptors exhibit distinctive patterns. In rods, weak expression of @entity4 is detected in perinuclear region and in the nucleus, whereas a strong nuclear labeling is evident in cones. @entity2 and @entity3 show a discrete pattern in developing retina with high expression at E11.5, little or no immunostaining by E15.5, and then postnatal expression overlapping with @entity4 in early born neurons (ganglion, amacrine and horizontal cells, and cones). Robust nuclear localization of DNMTs in cones compared to rods suggests a potential role of DNA methylation in differential remodeling of chromatin in these two specialized neurons. Our studies indicate that DNA methyltransferases contribute to the establishment and maturation of cell fates during retinal development.

title: Distinct nuclear localization patterns of DNA methyltransferases in developing and mature XXXX retina.

answer: @entity0


abstract: The recovery of exocrine and endocrine testicular function was studied in six @entity0 orchidectomized for an @entity4 -producing @entity7 . @entity5 disappeared in four @entity0 . The contralateral testis, whose volume was reduced, returned to normal size after 30 days. Sperm density returned to normal in only one of the four @entity0 in whom the preoperative sperm count was reduced. One day after unilateral orchidectomy, plasma @entity2 decreased to normal and @entity6 (T) fell about 50%. On the 10th postoperative day, plasma T [5.60 +/- 1.20 ng/ml (SD)] was normal. On day 120, T was higher than on day 10 (6.83 +/- 1.20 ng/ml). There was no significant @entity3 after a single injection of hCG (5000 IU) on day 10, and the T response was similar to that of normal @entity0 on day 120. Plasma FSH and LH were increased on the 10th postoperative day; they then decreased between 60 and 120 days after the operation but were still above the normal values on day 120. The FSH/LH ratio, which was 0.43 +/- 0.17 preoperatively returned to normal (1.60 +/- 0.25) 10 days postoperatively. In conclusion, after hemicastration for an @entity4 -secreting @entity1 , testicular hormonal secretion returns to normal within 120 days but spermatogenesis may still be impaired at this time.

title: XXXX with @entity5 : further studies--the recovery after unilateral orchidectomy.

answer: @entity7


abstract: The recovery of exocrine and endocrine testicular function was studied in six @entity0 orchidectomized for an @entity4 -producing @entity7 . @entity5 disappeared in four @entity0 . The contralateral testis, whose volume was reduced, returned to normal size after 30 days. Sperm density returned to normal in only one of the four @entity0 in whom the preoperative sperm count was reduced. One day after unilateral orchidectomy, plasma @entity2 decreased to normal and @entity6 (T) fell about 50%. On the 10th postoperative day, plasma T [5.60 +/- 1.20 ng/ml (SD)] was normal. On day 120, T was higher than on day 10 (6.83 +/- 1.20 ng/ml). There was no significant @entity3 after a single injection of hCG (5000 IU) on day 10, and the T response was similar to that of normal @entity0 on day 120. Plasma FSH and LH were increased on the 10th postoperative day; they then decreased between 60 and 120 days after the operation but were still above the normal values on day 120. The FSH/LH ratio, which was 0.43 +/- 0.17 preoperatively returned to normal (1.60 +/- 0.25) 10 days postoperatively. In conclusion, after hemicastration for an @entity4 -secreting @entity1 , testicular hormonal secretion returns to normal within 120 days but spermatogenesis may still be impaired at this time.

title: @entity7 with XXXX : further studies--the recovery after unilateral orchidectomy.

answer: @entity5


abstract: UNASSIGNED: @entity0 Ab-secreting cell (ASC) populations in circulation are not well studied. In addition to @entity6 ( @entity1 (+) @entity2 (+) @entity4 (lo/int) @entity5 (+)) cell and conventional plasmablast (PB) ( @entity1 - @entity2 (hi) @entity4 (hi)) cell populations, in this study, we identified a novel B cell population termed 20(+)38(hi) B cells ( @entity1 (+) @entity2 (hi) @entity4 (hi)) that spontaneously secretes Ab. At steady-state, 20(+)38(hi) B cells are distinct from PBs on the basis of @entity1 expression, amount of Ab production, frequency of mutation, and diversity of BCR repertoire. However, cytokine treatment of 20(+)38(hi) B cells induces loss of @entity1 and acquisition of @entity7 , suggesting that 20(+)38(hi) B cells are precursors to PBs or pre-PBs. We then evaluated similarities and differences among @entity1 (+) @entity2 (+) @entity4 (lo/int) @entity5 (+) @entity6 cells, @entity1 (+) @entity2 (hi) @entity4 (hi) 20(+)38(hi) B cells, @entity1 (-) @entity2 (hi) @entity4 (hi) PBs, and @entity1 (+) @entity2 (+) @entity4 (lo/int) @entity5 (-) memory B cells. We found that @entity6 cells differ from 20(+)38(hi) B cells and PBs in a number of ways, including Ag expression, morphological appearance, transcriptional profiling, Ab skewing, Ab repertoire, and secretory response to stimulation. In terms of gene expression, @entity6 cells align more closely with memory B cells than with 20(+)38(hi) B cells or PBs, but differ in that memory B cells do not express Ab secretion-related genes. We found that @entity6 cell Abs use Vh4-34, which is often associated with autoreactivity, 3- to 6-fold more often than other B cell populations. Along with selective production of IgM anti- @entity3 , these data suggest that @entity0 @entity6 cells might be preferentially selected for autoreactivity/natural specificity. In summary, our results indicate that @entity0 healthy adult peripheral blood at steady-state consists of three distinct ASC populations.

title: Distinctions among Circulating Antibody-Secreting Cell Populations, Including XXXX Cells, in @entity0 Adult Peripheral Blood.

answer: @entity6


abstract: UNASSIGNED: @entity0 Ab-secreting cell (ASC) populations in circulation are not well studied. In addition to @entity6 ( @entity1 (+) @entity2 (+) @entity4 (lo/int) @entity5 (+)) cell and conventional plasmablast (PB) ( @entity1 - @entity2 (hi) @entity4 (hi)) cell populations, in this study, we identified a novel B cell population termed 20(+)38(hi) B cells ( @entity1 (+) @entity2 (hi) @entity4 (hi)) that spontaneously secretes Ab. At steady-state, 20(+)38(hi) B cells are distinct from PBs on the basis of @entity1 expression, amount of Ab production, frequency of mutation, and diversity of BCR repertoire. However, cytokine treatment of 20(+)38(hi) B cells induces loss of @entity1 and acquisition of @entity7 , suggesting that 20(+)38(hi) B cells are precursors to PBs or pre-PBs. We then evaluated similarities and differences among @entity1 (+) @entity2 (+) @entity4 (lo/int) @entity5 (+) @entity6 cells, @entity1 (+) @entity2 (hi) @entity4 (hi) 20(+)38(hi) B cells, @entity1 (-) @entity2 (hi) @entity4 (hi) PBs, and @entity1 (+) @entity2 (+) @entity4 (lo/int) @entity5 (-) memory B cells. We found that @entity6 cells differ from 20(+)38(hi) B cells and PBs in a number of ways, including Ag expression, morphological appearance, transcriptional profiling, Ab skewing, Ab repertoire, and secretory response to stimulation. In terms of gene expression, @entity6 cells align more closely with memory B cells than with 20(+)38(hi) B cells or PBs, but differ in that memory B cells do not express Ab secretion-related genes. We found that @entity6 cell Abs use Vh4-34, which is often associated with autoreactivity, 3- to 6-fold more often than other B cell populations. Along with selective production of IgM anti- @entity3 , these data suggest that @entity0 @entity6 cells might be preferentially selected for autoreactivity/natural specificity. In summary, our results indicate that @entity0 healthy adult peripheral blood at steady-state consists of three distinct ASC populations.

title: Distinctions among Circulating Antibody-Secreting Cell Populations, Including @entity6 Cells, in XXXX Adult Peripheral Blood.

answer: @entity0


abstract: UNASSIGNED: Inflammation may initiate and promote @entity0 development, and be associated with elevated circulating levels of @entity2 markers. A total of eight 130 initially healthy @entity1 , participated in the population-based Troms   study (1994-2008). Pre-diagnostic high-sensitivity @entity3 (hs-CRP) was assessed. During 14.6  years of follow-up, a total of 192 @entity1 developed @entity0 . These cases were followed for additional 7.2  years. Detailed medical records were obtained. We observed an overall positive dose-response relationship between pre-diagnostic hs-CRP and @entity0 risk (hazard ratio (HR)  =  1.06, 95  % CI 1.01-1.11). Postmenopausal @entity1 with above median levels of hs-CRP (>1.2  mg/l) had a 1.42 (95  % CI 1.01-2.00) higher @entity0 risk compared to postmenopausal @entity1 with hs-CRP below median. Postmenopausal @entity1 , who were hormone replacement therapy non-users, and were in the middle tertile (0.8-1.9  mg/l), or highest tertile of hs-CRP (>1.9  mg/l), had a 2.31 (95  % CI 1.31-4.03) and 2.08 (95  % CI 1.16-3.76) higher @entity0 risk, respectively, compared with @entity1 in the lowest tertile. For each unit increase in pre-diagnostic hs-CRP levels (mg/l), we observed an 18  % increase in disease-free interval (95  % CI 0.70-0.97), and a 22  % reduction in overall mortality (95  % CI 0.62-0.98). Our study supports a positive association between pre-diagnostic hs-CRP and @entity0 risk. In contrast, increased pre-diagnostic hs-CRP was associated with improved overall mortality, but our findings are based on a small sample size, and should be interpreted with caution.

title: Pre-diagnostic high-sensitive XXXX and @entity0 risk, recurrence, and survival.

answer: @entity3


abstract: UNASSIGNED: Inflammation may initiate and promote @entity0 development, and be associated with elevated circulating levels of @entity2 markers. A total of eight 130 initially healthy @entity1 , participated in the population-based Troms   study (1994-2008). Pre-diagnostic high-sensitivity @entity3 (hs-CRP) was assessed. During 14.6  years of follow-up, a total of 192 @entity1 developed @entity0 . These cases were followed for additional 7.2  years. Detailed medical records were obtained. We observed an overall positive dose-response relationship between pre-diagnostic hs-CRP and @entity0 risk (hazard ratio (HR)  =  1.06, 95  % CI 1.01-1.11). Postmenopausal @entity1 with above median levels of hs-CRP (>1.2  mg/l) had a 1.42 (95  % CI 1.01-2.00) higher @entity0 risk compared to postmenopausal @entity1 with hs-CRP below median. Postmenopausal @entity1 , who were hormone replacement therapy non-users, and were in the middle tertile (0.8-1.9  mg/l), or highest tertile of hs-CRP (>1.9  mg/l), had a 2.31 (95  % CI 1.31-4.03) and 2.08 (95  % CI 1.16-3.76) higher @entity0 risk, respectively, compared with @entity1 in the lowest tertile. For each unit increase in pre-diagnostic hs-CRP levels (mg/l), we observed an 18  % increase in disease-free interval (95  % CI 0.70-0.97), and a 22  % reduction in overall mortality (95  % CI 0.62-0.98). Our study supports a positive association between pre-diagnostic hs-CRP and @entity0 risk. In contrast, increased pre-diagnostic hs-CRP was associated with improved overall mortality, but our findings are based on a small sample size, and should be interpreted with caution.

title: Pre-diagnostic high-sensitive @entity3 and XXXX risk, recurrence, and survival.

answer: @entity0


abstract: @entity3 in the young are rare. Only 14 such abscesses have been seen at Texas @entity0 's Hospital since 1968. Most abscesses developed in association with @entity1 (5), although @entity4 and @entity6 were precipitating causes in two @entity0 and one @entity0 , respectively. The latter three @entity0 ' cases are reviewed in detail. Clinical and bacteriologic findings in all @entity0 are discussed. There were signs of @entity2 in nine @entity0 (64%). All abscesses were drained; in several, repeated drainage was necessary. Anaerobic organisms were recovered in six @entity0 (43%), aerobic organisms were recovered in five (36%), and both were recovered in two (14%). In one @entity0 no growth was reported. Antimicrobial therapy was administered to all @entity0 but one, whose abscess was completely excised. Morbidity and mortality remained significant: three @entity0 (21%) died and one has a @entity5 .

title: XXXX in the young.

answer: @entity3


abstract: The effects of @entity1 on a @entity0 electroencephalographic event related potential (ERP) were measured. Forty-eight subjects received one of three IV doses (0.2, 0.4, or 0.6 mg/kg) and placebo. Thirty-three subjects received one of three oral doses (2, 3, or 4 mg/kg). All IV and oral doses reduced amplitude of the auditory ERP @entity3 and @entity2 components during the oddball task. @entity3 latency decreased. N100 amplitude was reduced only after IV administration. The changes in ERPs occurred during the period of peak cardiovascular and subjective effects. The amplitude reduction in ERP components occurring before the @entity2 component is consistent with decrements in attention, specifically selective attention. The @entity2 amplitude reduction after @entity1 suggests a disruption of stimulus evaluation resources. The findings are inconsistent with the notion that stimulants affect only response selection and execution. The degree to which stimulants alter cognitive processes prior to response selection may depend on the magnitude of the cardiovascular, subjective, and probably other noncognitive effects.

title: Information processing components of the auditory event related potential are reduced by XXXX .

answer: @entity1


abstract: UNASSIGNED: One of the most significant health problems in the American continent in terms of @entity0 health, and socioeconomic impact is @entity5 , caused by the protozoan parasite @entity6 . Infection was originally transmitted by reduviid insects, congenitally from mother to fetus, and by oral ingestion in sylvatic/rural environments, but blood transfusions, organ transplants, laboratory accidents, and sharing of contaminated syringes also contribute to modern day transmission. Likewise, @entity5 used to be endemic from Northern Mexico to Argentina, but migrations have earned it global. The parasite has a complex life cycle, infecting different species, and invading a variety of cells - including muscle and nerve cells of the heart and gastrointestinal tract - in the @entity0 host. @entity0 @entity2 outcome is a potentially fatal @entity3 , and @entity4 . In absence of a vaccine, vector control and treatment of @entity0 are the only tools to control the disease. Unfortunately, the only drugs now available for @entity5 , Nifurtimox and @entity7 , are relatively toxic for adult @entity0 , and require prolonged administration. @entity7 is the first choice for @entity5 treatment due to its lower side effects than @entity8 . However, different strategies are being sought to overcome @entity7 's @entity1 including shorter or intermittent administration schedules-either alone or in combination with other drugs. In addition, a long list of compounds has shown trypanocidal activity, ranging from natural products to specially designed molecules, re-purposing drugs commercialized to treat other maladies, and homeopathy. In the present review, we will briefly summarize the upturns of current treatment of @entity5 , discuss the increment on research and scientific publications about this topic, and give an overview of the state-of-the-art research aiming to produce an alternative medication to treat @entity6 @entity2 .

title: Current drug therapy and pharmaceutical challenges for XXXX .

answer: @entity5


abstract: Concomitant presentation of @entity4 ( @entity4 ) and @entity5 is a rare entity. A primary malignancy such as @entity8 ( @entity8 ) may cause suppression of the cell-mediated immunity, which predisposes to a concomitant @entity4 . We report a case of an 18-year-old @entity0 , who presented with @entity3 and was found to have pallor, generalised @entity9 , @entity6 , @entity7 and pedal @entity1 . Ultrasound of the abdomen revealed enlarged lymph nodes in the para-aortic and peripancreatic region. On chest contrast-enhanced CT, calcified mediastinal lymph nodes were seen. A surgical biopsy of a cervical lymph node was performed, which revealed @entity2 surrounded by epithelioid cells along with diffuse nodal architectural effacement by large atypical lymphoid cells. Numerous Reed Sternberg cells were also seen. Immunohistochemistry confirmed diagnosis of @entity8 . The same lymph node came out to be positive for mycobacterium @entity4 on polymerised chain reaction. The @entity0 was given antitubercular therapy concomitantly with chemotherapy for @entity8 , and improved with treatment.

title: Simultaneous occurrence of XXXX and tubercular lymphadenitis in the same cervical lymph node: a rare presentation.

answer: @entity8


abstract: UNASSIGNED: Many randomized clinical trials (RCTs) have investigated the efficacy and safety of renin-angiotensin system inhibitors (RASIs) plus @entity3 channel blockers (CCBs), compared with other two-drug combinations, but systematic assessment in this aspect is still lacking. We carried out the present meta-analysis of randomized controlled trials to evaluate the long-term effect and safety of RASIs plus CCBs. Literatures were searched in MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials in September 2014. A fixed-effect model was used to estimate the pooled effect of trials identified. Thirty-four trials with 41   694 @entity0 were included. Compared with RASIs plus diuretics, RASIs plus CCBs @entity1 (CV) events (relative risk (RR) 0.82, 95% confidence interval (CI): 0.75, 0.91, adjusted RR (ARR) 1.7%) and withdrawals due to adverse effect (WDAE) (RR 0.87, 95% CI: 0.80, 0.94, @entity4 .3%). Compared with CCBs plus diuretics, RASIs plus CCBs decreased WDAE (RR 0.63, 95% CI: 0.45, 0.90, @entity4 .1%). Our meta-analysis indicates that RASIs plus CCBs provide a superior safety and prevention of CV events to RASIs plus diuretics, whereas this combination is also safer than CCBs plus diuretics. We also raise a new hypothesis. More high-quality RCTs focused on hard end points with CV, cerebrovascular and renal events are needed to confirm the hypothesis we have brought out.Journal of @entity0 @entity2 advance online publication, 7 January 2016; doi:10.1038/jhh.2015.125.

title: Combination therapy of renin-angiotensin system inhibitors plus @entity3 channel blockers versus other two-drug combinations for XXXX : a systematic review and meta-analysis.

answer: @entity2


abstract: UNASSIGNED: Many randomized clinical trials (RCTs) have investigated the efficacy and safety of renin-angiotensin system inhibitors (RASIs) plus @entity3 channel blockers (CCBs), compared with other two-drug combinations, but systematic assessment in this aspect is still lacking. We carried out the present meta-analysis of randomized controlled trials to evaluate the long-term effect and safety of RASIs plus CCBs. Literatures were searched in MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials in September 2014. A fixed-effect model was used to estimate the pooled effect of trials identified. Thirty-four trials with 41   694 @entity0 were included. Compared with RASIs plus diuretics, RASIs plus CCBs @entity1 (CV) events (relative risk (RR) 0.82, 95% confidence interval (CI): 0.75, 0.91, adjusted RR (ARR) 1.7%) and withdrawals due to adverse effect (WDAE) (RR 0.87, 95% CI: 0.80, 0.94, @entity4 .3%). Compared with CCBs plus diuretics, RASIs plus CCBs decreased WDAE (RR 0.63, 95% CI: 0.45, 0.90, @entity4 .1%). Our meta-analysis indicates that RASIs plus CCBs provide a superior safety and prevention of CV events to RASIs plus diuretics, whereas this combination is also safer than CCBs plus diuretics. We also raise a new hypothesis. More high-quality RCTs focused on hard end points with CV, cerebrovascular and renal events are needed to confirm the hypothesis we have brought out.Journal of @entity0 @entity2 advance online publication, 7 January 2016; doi:10.1038/jhh.2015.125.

title: Combination therapy of renin-angiotensin system inhibitors plus XXXX channel blockers versus other two-drug combinations for @entity2 : a systematic review and meta-analysis.

answer: @entity3


abstract: OBJECTIVES: Prevention of type 2 @entity1 (T2DM) is a priority in healthcare, but there is a lack of evidence investigating how to effectively translate prevention research into a UK primary care setting. We assessed whether a structured education programme targeting lifestyle and behaviour change was effective at preventing progression to T2DM in @entity0 with @entity1 . MATERIALS AND METHODS: Forty-four general practices were randomised to receive either standard care or a 6hour group structured education programme with an annual refresher course, and regular phone contact. @entity0 were followed up for 3years. The primary outcome was progression to T2DM. RESULTS: Eight hundred and eighty @entity0 were included (36% female, mean age 64years, 16% ethnic minority group); 131 @entity0 developed T2DM. There was a non-significant 26% reduced risk of developing T2DM in the intervention arm compared to standard care (HR 0.74, 95% CI 0.48, 1.14, p=0.18). The reduction in T2DM risk when excluding those who did not attend the initial education session was also non-significant (HR 0.65, 0.41, 1.03, p=0.07). There were statistically significant improvements in HbA1c (-0.06, -0.11, -0.01), LDL @entity2 (-0.08, -0.15, -0.01), sedentary time (-26.29, -45.26, -7.32) and step count (498.15, 162.10, 834.20) when data were analysed across all time points. CONCLUSIONS: This study suggests that a relatively low resource, pragmatic @entity1 prevention programme resulted in modest benefits to biomedical, lifestyle and psychosocial outcomes, however the reduction to the risk of T2DM did not reach significance. The findings have important implications for future research and primary care.

title: A community based primary prevention programme for type 2 XXXX integrating identification and lifestyle intervention for prevention: the Let's Prevent @entity1 cluster randomised controlled trial.

answer: @entity1


abstract: OBJECTIVES: Prevention of type 2 @entity1 (T2DM) is a priority in healthcare, but there is a lack of evidence investigating how to effectively translate prevention research into a UK primary care setting. We assessed whether a structured education programme targeting lifestyle and behaviour change was effective at preventing progression to T2DM in @entity0 with @entity1 . MATERIALS AND METHODS: Forty-four general practices were randomised to receive either standard care or a 6hour group structured education programme with an annual refresher course, and regular phone contact. @entity0 were followed up for 3years. The primary outcome was progression to T2DM. RESULTS: Eight hundred and eighty @entity0 were included (36% female, mean age 64years, 16% ethnic minority group); 131 @entity0 developed T2DM. There was a non-significant 26% reduced risk of developing T2DM in the intervention arm compared to standard care (HR 0.74, 95% CI 0.48, 1.14, p=0.18). The reduction in T2DM risk when excluding those who did not attend the initial education session was also non-significant (HR 0.65, 0.41, 1.03, p=0.07). There were statistically significant improvements in HbA1c (-0.06, -0.11, -0.01), LDL @entity2 (-0.08, -0.15, -0.01), sedentary time (-26.29, -45.26, -7.32) and step count (498.15, 162.10, 834.20) when data were analysed across all time points. CONCLUSIONS: This study suggests that a relatively low resource, pragmatic @entity1 prevention programme resulted in modest benefits to biomedical, lifestyle and psychosocial outcomes, however the reduction to the risk of T2DM did not reach significance. The findings have important implications for future research and primary care.

title: A community based primary prevention programme for type 2 @entity1 integrating identification and lifestyle intervention for prevention: the Let's Prevent XXXX cluster randomised controlled trial.

answer: @entity1


abstract: BACKGROUND AND PURPOSE: The PED is a new endoluminal construct designed to exclude @entity8 from the parent cerebrovasculature. We report the very late (>1 year) @entity9 of PED constructs in 2 @entity0 . RESULTS: Two @entity0 with very large fusiform basilar trunk @entity8 underwent parent artery reconstruction with the PED. Both @entity0 were maintained on dual antiplatelet therapy throughout the first year following treatment. Follow-up conventional angiography, performed 12 months after treatment, demonstrated, in both @entity0 , @entity9 of most of the @entity8 with minimal residual flow through the construct and into the @entity8 fundus. In response to the @entity2 , @entity11 was discontinued ( @entity4 therapy was maintained). Both @entity0 presented with symptomatic acute occlusions of the PED constructs within 14 days of @entity11 discontinuation. DISCUSSION: @entity0 1 presented with constitutional symptoms that progressed to severe @entity1 without other neurologic signs or symptoms. Occlusion of the PED construct was confirmed with conventional angiography. MR imaging demonstrated no evidence of @entity10 or @entity5 . The @entity1 were managed successfully with @entity6 therapy. @entity0 2 presented with a syndrome of @entity7 with @entity3 . Complete occlusion was confirmed on angiography. Emergent thrombolysis with mechanical revascularization was performed successfully; however, the @entity0 ultimately succumbed to the @entity10 . CONCLUSIONS: It appears that flow-diverting constructs built across large circumferential @entity8 may remain thrombogenic for much longer than conventional intracranial or peripheral bare metal stents. Constructs in these @entity0 may remain susceptible to very late @entity9 , >1 year after implantation. These @entity0 likely require long-term dual antiplatelet therapy (>1 year) to provide adequate prophylaxis against @entity9 . If these types of @entity8 demonstrate persistent @entity2 months after PED reconstruction, operators should consider the placement of additional devices as an alternative to the discontinuation of 1 of the antiplatelet medications.

title: Very late @entity9 of flow-diverting constructs after the treatment of large fusiform posterior circulation XXXX .

answer: @entity8


abstract: BACKGROUND AND PURPOSE: The PED is a new endoluminal construct designed to exclude @entity8 from the parent cerebrovasculature. We report the very late (>1 year) @entity9 of PED constructs in 2 @entity0 . RESULTS: Two @entity0 with very large fusiform basilar trunk @entity8 underwent parent artery reconstruction with the PED. Both @entity0 were maintained on dual antiplatelet therapy throughout the first year following treatment. Follow-up conventional angiography, performed 12 months after treatment, demonstrated, in both @entity0 , @entity9 of most of the @entity8 with minimal residual flow through the construct and into the @entity8 fundus. In response to the @entity2 , @entity11 was discontinued ( @entity4 therapy was maintained). Both @entity0 presented with symptomatic acute occlusions of the PED constructs within 14 days of @entity11 discontinuation. DISCUSSION: @entity0 1 presented with constitutional symptoms that progressed to severe @entity1 without other neurologic signs or symptoms. Occlusion of the PED construct was confirmed with conventional angiography. MR imaging demonstrated no evidence of @entity10 or @entity5 . The @entity1 were managed successfully with @entity6 therapy. @entity0 2 presented with a syndrome of @entity7 with @entity3 . Complete occlusion was confirmed on angiography. Emergent thrombolysis with mechanical revascularization was performed successfully; however, the @entity0 ultimately succumbed to the @entity10 . CONCLUSIONS: It appears that flow-diverting constructs built across large circumferential @entity8 may remain thrombogenic for much longer than conventional intracranial or peripheral bare metal stents. Constructs in these @entity0 may remain susceptible to very late @entity9 , >1 year after implantation. These @entity0 likely require long-term dual antiplatelet therapy (>1 year) to provide adequate prophylaxis against @entity9 . If these types of @entity8 demonstrate persistent @entity2 months after PED reconstruction, operators should consider the placement of additional devices as an alternative to the discontinuation of 1 of the antiplatelet medications.

title: Very late XXXX of flow-diverting constructs after the treatment of large fusiform posterior circulation @entity8 .

answer: @entity9


abstract: The histopathologic interpretation of proliferative nodules (PNs) in @entity6 can present significant challenges as some PNs may exhibit atypical features that make the distinction from @entity2 . We compared histologic features, Ki-67%, PHH3, and CD117% expression levels by immunohistochemistry in 18 benign and 25 atypical PNs (from 41 @entity0 ) with that of background @entity5 (of these 43 cases), 10 @entity5 , and 3 dermal @entity2 arising in @entity1 . In addition, we evaluated the presence of @entity3 , @entity9 , @entity8 , @entity4 , and @entity7 mutations in all groups using the SNaPshot Multiplex System. Follow-up was available on 19 @entity0 (9 benign and 10 atypical PNs) (range, 2 to 20 y; median, 8 y) and all were alive with no evidence of disease. The specific histologic features of atypical PNs, such as sharp demarcation (P<0.001), expansile growth (P<0.001), epidermal effacement (P<0.001), nuclear pleomorphism (P<0.001), and increased mitoses (P<0.001), differed significantly from those of benign PNs. Immunohistochemical results showed that Ki-67% and PHH3 scores, but not CD117% expression, were significantly higher (P<0.05) in atypical PNs. Molecular analyses showed that the PNs and background @entity6 of the giant @entity5 possess more frequent @entity7 mutations and infrequent @entity3 mutations when compared with those of the remaining cases. These findings suggest that histologic features and Ki-67 and PHH3 expression levels are the strongest parameters to distinguish between benign versus atypical PNs. The immunohistochemical results suggest that atypical PNs are distinct borderline lesions residing between benign PNs and dermal @entity2 . Although numerous mutations are detected in the samples, the diagnostic use of molecular analysis in this regard is limited.

title: Proliferative nodules arising within XXXX : a histologic, immunohistochemical, and molecular analyses of 43 cases.

answer: @entity6


abstract: Prenatal selective @entity1 reuptake inhibitor (SSRI) exposure increases the risk for adverse neonatal behavioral outcomes; although it is unknown whether altered brain function is present before birth. We investigated fetal vascular and heart rate changes at 36-wk gestation in SSRI-treated @entity0 with @entity2 (n = 29) [exposed (EXP)] and controls (n = 45) [non-EXP (NEXP)]. @entity3 (MCA) flow parameters and heart rate characteristics were obtained during pre-SSRI dose morning and postdose afternoon sessions. Maternal mood and cord Hb and hematocrit were measured. Basal fetal heart rate (fHR) did not differ between groups or across the day. The fHR short- and long-term variations, accelerations, and duration of high variability episodes remained lower and did not change across the day in EXP, whereas all increased significantly in NEXP. In both groups, MCA flow velocity and volume flow increased significantly across the day. EXP MCA pulsatility index was significantly lower, as was MCA cross-sectional area. EXP cord Hb and hematocrit were significantly increased. Prenatal SSRI exposure reduced fetal MCA flow resistance and fHR variability, before and after an SSRI dose, controlling for maternal mood. These changes and the SSRI-related increased red cell indices suggest possible @entity4 .

title: Third trimester fetal heart rate and Doppler middle cerebral artery blood flow velocity characteristics during prenatal selective XXXX reuptake inhibitor exposure.

answer: @entity1


abstract: The number of reported cases of smooth @entity8 (SMT) arising in @entity0 with @entity4 has been increasing since the mid-1990s. The aim of this study is to characterize the epidemiology, clinical manifestations, pathologic features, prognosis and, management of @entity7 -related SMT (EBV-SMT) in @entity0 with @entity4 . An English language literature search identified 53 articles including 64 reported cases of EBV-SMT. The majority of these reports involved @entity0 who were young, severely immunosuppressed, and had multifocal @entity1 . The central nervous system was the most common site to be involved. Histologically, @entity1 had smooth muscle features and were immunoreactive for muscle markers and all but two @entity1 demonstrated the presence of EBV by either immunohistochemistry, in situ hybridization, and/or PCR. While mitoses and/or @entity2 were used to separate @entity6 from @entity5 , these features did not correlate with clinical outcome. Treatment included primarily resection, and less often radiotherapy, chemotherapy and highly active antiretroviral therapy (HAART). Overall, EBV-SMTs appear to have variable @entity3 and clinical outcome and may exhibit a more favorable prognosis compared to @entity5 . Tumor-related death from EBV-SMT occurred in only 4 of 51 @entity0 .

title: XXXX -Related EBV-Associated Smooth Muscle Tumors: A Review of 64 Published Cases.

answer: @entity4


abstract: Tau is the proteinaceous component of intraneuronal aggregates common to @entity1 called @entity7 , including @entity4 type 1. In @entity4 type 1, the presence of @entity3 aggregates is associated with a @entity2 -splicing of Tau. A toxic gain-of-function at the @entity6 level is a major etiological factor responsible for the @entity2 -splicing of several transcripts in @entity4 type 1. These are probably the consequence of a loss of @entity9 ( @entity9 ) function or gain of @entity5 and ETR3-like factor 1 ( @entity5 ) splicing function. Whether these two dysfunctions occur together or separately and whether all @entity2 -splicing events in @entity4 type 1 brain result from one or both of these dysfunctions remains unknown. Here, we analyzed the splicing of Tau exons 2 and 10 in the brain of @entity4 type 1 @entity0 . Two @entity4 type 1 @entity0 showed a @entity2 -splicing of exon 10 whereas exon 2-inclusion was reduced in all @entity4 type 1 @entity0 . In order to determine the potential factors responsible for exon 10 @entity2 -splicing, we studied the effect of the splicing factors @entity9 ( @entity9 ), @entity5 and ETR3-like factor 1 ( @entity5 ), @entity5 and ETR3-like factor 2 ( @entity11 ), and @entity5 and ETR3-like factor 4 ( @entity10 ) or a dominant-negative @entity5 and ETR-3 like factor ( @entity8 ) factor on Tau exon 10 splicing by ectopic expression or siRNA. Interestingly, the inclusion of Tau exon 10 is reduced by @entity5 and ETR3-like factor 2 ( @entity11 ) whereas it is insensitive to the loss-of-function of @entity9 ( @entity9 ), @entity5 and ETR3-like factor 1 ( @entity5 ) gain-of-function, or a dominant-negative of @entity5 and ETR-3 like factor ( @entity8 ) factor. Moreover, we observed an increased expression of @entity5 and ETR3-like factor 2 ( @entity11 ) only in the brain of @entity4 type 1 @entity0 with a @entity2 -splicing of exon 10. Taken together, our results indicate the occurrence of a @entity2 -splicing event in @entity4 type 1 that is induced neither by a loss of @entity9 ( @entity9 ) function nor by a gain of @entity5 and ETR3-like factor 1 ( @entity5 ) function but is rather associated to @entity5 and ETR3-like factor 2 ( @entity11 ) gain-of-function.

title: @entity2 -splicing of Tau exon 10 in XXXX type 1 is reproduced by overexpression of @entity11 but not by @entity9 silencing.

answer: @entity4


abstract: Tau is the proteinaceous component of intraneuronal aggregates common to @entity1 called @entity7 , including @entity4 type 1. In @entity4 type 1, the presence of @entity3 aggregates is associated with a @entity2 -splicing of Tau. A toxic gain-of-function at the @entity6 level is a major etiological factor responsible for the @entity2 -splicing of several transcripts in @entity4 type 1. These are probably the consequence of a loss of @entity9 ( @entity9 ) function or gain of @entity5 and ETR3-like factor 1 ( @entity5 ) splicing function. Whether these two dysfunctions occur together or separately and whether all @entity2 -splicing events in @entity4 type 1 brain result from one or both of these dysfunctions remains unknown. Here, we analyzed the splicing of Tau exons 2 and 10 in the brain of @entity4 type 1 @entity0 . Two @entity4 type 1 @entity0 showed a @entity2 -splicing of exon 10 whereas exon 2-inclusion was reduced in all @entity4 type 1 @entity0 . In order to determine the potential factors responsible for exon 10 @entity2 -splicing, we studied the effect of the splicing factors @entity9 ( @entity9 ), @entity5 and ETR3-like factor 1 ( @entity5 ), @entity5 and ETR3-like factor 2 ( @entity11 ), and @entity5 and ETR3-like factor 4 ( @entity10 ) or a dominant-negative @entity5 and ETR-3 like factor ( @entity8 ) factor on Tau exon 10 splicing by ectopic expression or siRNA. Interestingly, the inclusion of Tau exon 10 is reduced by @entity5 and ETR3-like factor 2 ( @entity11 ) whereas it is insensitive to the loss-of-function of @entity9 ( @entity9 ), @entity5 and ETR3-like factor 1 ( @entity5 ) gain-of-function, or a dominant-negative of @entity5 and ETR-3 like factor ( @entity8 ) factor. Moreover, we observed an increased expression of @entity5 and ETR3-like factor 2 ( @entity11 ) only in the brain of @entity4 type 1 @entity0 with a @entity2 -splicing of exon 10. Taken together, our results indicate the occurrence of a @entity2 -splicing event in @entity4 type 1 that is induced neither by a loss of @entity9 ( @entity9 ) function nor by a gain of @entity5 and ETR3-like factor 1 ( @entity5 ) function but is rather associated to @entity5 and ETR3-like factor 2 ( @entity11 ) gain-of-function.

title: @entity2 -splicing of Tau exon 10 in @entity4 type 1 is reproduced by overexpression of XXXX but not by @entity9 silencing.

answer: @entity11


abstract: Tau is the proteinaceous component of intraneuronal aggregates common to @entity1 called @entity7 , including @entity4 type 1. In @entity4 type 1, the presence of @entity3 aggregates is associated with a @entity2 -splicing of Tau. A toxic gain-of-function at the @entity6 level is a major etiological factor responsible for the @entity2 -splicing of several transcripts in @entity4 type 1. These are probably the consequence of a loss of @entity9 ( @entity9 ) function or gain of @entity5 and ETR3-like factor 1 ( @entity5 ) splicing function. Whether these two dysfunctions occur together or separately and whether all @entity2 -splicing events in @entity4 type 1 brain result from one or both of these dysfunctions remains unknown. Here, we analyzed the splicing of Tau exons 2 and 10 in the brain of @entity4 type 1 @entity0 . Two @entity4 type 1 @entity0 showed a @entity2 -splicing of exon 10 whereas exon 2-inclusion was reduced in all @entity4 type 1 @entity0 . In order to determine the potential factors responsible for exon 10 @entity2 -splicing, we studied the effect of the splicing factors @entity9 ( @entity9 ), @entity5 and ETR3-like factor 1 ( @entity5 ), @entity5 and ETR3-like factor 2 ( @entity11 ), and @entity5 and ETR3-like factor 4 ( @entity10 ) or a dominant-negative @entity5 and ETR-3 like factor ( @entity8 ) factor on Tau exon 10 splicing by ectopic expression or siRNA. Interestingly, the inclusion of Tau exon 10 is reduced by @entity5 and ETR3-like factor 2 ( @entity11 ) whereas it is insensitive to the loss-of-function of @entity9 ( @entity9 ), @entity5 and ETR3-like factor 1 ( @entity5 ) gain-of-function, or a dominant-negative of @entity5 and ETR-3 like factor ( @entity8 ) factor. Moreover, we observed an increased expression of @entity5 and ETR3-like factor 2 ( @entity11 ) only in the brain of @entity4 type 1 @entity0 with a @entity2 -splicing of exon 10. Taken together, our results indicate the occurrence of a @entity2 -splicing event in @entity4 type 1 that is induced neither by a loss of @entity9 ( @entity9 ) function nor by a gain of @entity5 and ETR3-like factor 1 ( @entity5 ) function but is rather associated to @entity5 and ETR3-like factor 2 ( @entity11 ) gain-of-function.

title: XXXX -splicing of Tau exon 10 in @entity4 type 1 is reproduced by overexpression of @entity11 but not by @entity9 silencing.

answer: @entity2


abstract: Tau is the proteinaceous component of intraneuronal aggregates common to @entity1 called @entity7 , including @entity4 type 1. In @entity4 type 1, the presence of @entity3 aggregates is associated with a @entity2 -splicing of Tau. A toxic gain-of-function at the @entity6 level is a major etiological factor responsible for the @entity2 -splicing of several transcripts in @entity4 type 1. These are probably the consequence of a loss of @entity9 ( @entity9 ) function or gain of @entity5 and ETR3-like factor 1 ( @entity5 ) splicing function. Whether these two dysfunctions occur together or separately and whether all @entity2 -splicing events in @entity4 type 1 brain result from one or both of these dysfunctions remains unknown. Here, we analyzed the splicing of Tau exons 2 and 10 in the brain of @entity4 type 1 @entity0 . Two @entity4 type 1 @entity0 showed a @entity2 -splicing of exon 10 whereas exon 2-inclusion was reduced in all @entity4 type 1 @entity0 . In order to determine the potential factors responsible for exon 10 @entity2 -splicing, we studied the effect of the splicing factors @entity9 ( @entity9 ), @entity5 and ETR3-like factor 1 ( @entity5 ), @entity5 and ETR3-like factor 2 ( @entity11 ), and @entity5 and ETR3-like factor 4 ( @entity10 ) or a dominant-negative @entity5 and ETR-3 like factor ( @entity8 ) factor on Tau exon 10 splicing by ectopic expression or siRNA. Interestingly, the inclusion of Tau exon 10 is reduced by @entity5 and ETR3-like factor 2 ( @entity11 ) whereas it is insensitive to the loss-of-function of @entity9 ( @entity9 ), @entity5 and ETR3-like factor 1 ( @entity5 ) gain-of-function, or a dominant-negative of @entity5 and ETR-3 like factor ( @entity8 ) factor. Moreover, we observed an increased expression of @entity5 and ETR3-like factor 2 ( @entity11 ) only in the brain of @entity4 type 1 @entity0 with a @entity2 -splicing of exon 10. Taken together, our results indicate the occurrence of a @entity2 -splicing event in @entity4 type 1 that is induced neither by a loss of @entity9 ( @entity9 ) function nor by a gain of @entity5 and ETR3-like factor 1 ( @entity5 ) function but is rather associated to @entity5 and ETR3-like factor 2 ( @entity11 ) gain-of-function.

title: @entity2 -splicing of Tau exon 10 in @entity4 type 1 is reproduced by overexpression of @entity11 but not by XXXX silencing.

answer: @entity9


abstract: INTRODUCTION: We assessed the effectiveness of mandibular advancement device (MAD) on 113 @entity0 having consulted in our specialized unit for @entity1 ( @entity1 ), from January 2005 to January 2010. METHODS: We included all adult @entity0 referred by pulmonologists for @entity1 . The data collected were gender, age, BMI, dental occlusion, presentation of retromandibulism, @entity1 index (AHI) at diagnosis, and MAD effectiveness (AHI, compliance, satisfaction, tolerance). RESULTS: One hundred and thirteen @entity0 were included, 83 @entity0 and 30 @entity0 , with an average age of 53.6 years, and average BMI of 26.9. Fifty-eight @entity0 (55.8%) used the MAD regularly, 17 (16.4%) irregularly, and 29 (27.9%) stopped using it. Fifty-seven @entity0 (54.8%) were very satisfied, 20 (19.2%) somewhat satisfied, and 27 (26%) not at all. The average AHI with MAD was 13.3 (  10.3) and the average improvement of AHI was 19 (  14.1). Twenty-seven @entity0 (28.7%) were cured, 46 (48.9%) presented with an AHI decrease greater than 50%, and for 21 (22.3%) the treatment failed. DISCUSSION: The sample of @entity0 in this study has the same characteristics as the general apneic population. Adherence and satisfaction were satisfactory. AHI results were also good but seemed low compared to other studies. This was due to more stringent criteria for cure, more in line with the overall management. No criterion for inclusion was predictive of good tolerance and no score predictive of success could be established. However, the improvement in AHI was significantly correlated to the @entity0 's BMI and its diagnostic AHI.

title: [Mandibular advancement device: a 5-year long experience in XXXX ].

answer: @entity1


abstract: Clinical trials of UFT have been conducted on @entity0 with far-advanced @entity6 with distant @entity1 . All @entity0 had evaluable lesions which had shown no change or progressive disease under prior therapy. Five of these cases had received Interferon as prior therapy. Thus far, the antitumor effects of the drug were evaluated in 8 cases according to the criteria proposed by the Koyama-Saito group. Partial response was obtained in 3 of 8 @entity0 (37.5%). Two @entity0 showed no change and three @entity0 showed @entity3 caused @entity5 and @entity4 in each of @entity0 . To measure the @entity7 level in the @entity2 and normal kidney tissues UFT was administered at 600 mg per day on the day before radical nephrectomy in 2 @entity0 , who had received embolization therapy of the renal artery prior to surgery. The @entity7 level was higher in @entity2 and normal kidney tissues than in serum, but there was no significant difference between @entity2 and normal kidney tissues. The embolization therapy of the renal artery may have been responsible for this result. UFT is one of the most useful drugs for the treatment of @entity6 .

title: [Effects of UFT in advanced XXXX ].

answer: @entity6


abstract: PURPOSE: There is a lack of consensus regarding biomechanical effects of unloader braces for the treatment of @entity2 ( @entity2 ) of the knee. The purpose of this study was to perform a systematic review of studies examining the biomechanical effect of unloader braces. METHODS: A systematic search for articles about the biomechanical effect of unloader braces was performed. Primary outcome measure was the influence of the brace on the knee adduction moment. Data sources were Pubmed central and google scholar. RESULTS: Twenty-four articles were included. Twenty articles showed that valgus unloader braces significantly decrease the knee adduction moment. Seven of those studies reported a decrease of @entity1 in braced @entity0 (secondary outcome measure). Positive effects on the knee adduction moment could be found for custom made braces for conventional knee braces and for a foot ankle orthosis. Four studies could not show any effect of knee unloader braces on the knee adduction moment although one of these studies found @entity1 in braced @entity0 . One of these studies examined healthy @entity0 with a @entity3 . CONCLUSION: This systematic review could demonstrate evidence that unloader braces reduce the adduction moment of the knee. Foresighted, a systematic review about the clinical effect of unloader braces is required.

title: Biomechanical effect of unloader braces for XXXX of the knee: a systematic review (CRD 42015026136).

answer: @entity2


abstract: Macrophage, fibroblast, and HeLa cell cultures have been infected with @entity0 , and observations have been made on parasite entry and fate. A special procedure was devised for studying the entry of @entity1 by electron microscopy. Toxoplasmas were centrifuged onto the cells in the cold; fixation 1-3 min after warming yielded specimens showing numerous examples of parasites in the process of entering cells. The mechanism of entry into macrophages, fibroblasts, and HeLa cells was in all cases by phagocytosis. Micropseudopods were extended by the cells to envelop the attached parasites in a typical phagocytic vacuole. Apparently the @entity1 stimulated this response of HeLa cells and fibroblasts, cell types not usually phagocytic. No instance was seen of penetration of @entity1 through the cell membrane, or of parasites located free in the cytoplasm. Essentially all of the @entity1 that entered HeLa cells divided with a generation time of 9 hr; the parasites formed large rosettes situated in vacuoles, eventually leading to host cell rupture. Macrophages took in larger numbers of @entity1 than did HeLa cells, but approximately half of the parasites inside of macrophages degenerated within a few hours. The surviving @entity1 in macrophages divided every 8 hr, forming rosettes and eventually rupturing the cells.

title: The interaction between XXXX and mammalian cells. I. Mechanism of entry and intracellular fate of the parasite.

answer: @entity0


abstract: Surgical denervation of kidneys results in interruption of both afferent and efferent @entity0 . We attempted selective efferent renal denervation in @entity1 by slow infusions of @entity4 ( @entity4 ) into the right renal artery. Integrity of efferent @entity0 was assessed by chemical and physiological methods and by measuring responses of mean arterial blood pressure (MAP) and heart rate (HR) to intrarenal (ir) infusion of @entity3 in conscious @entity1 . Results were compared with those in surgically denervated and ir saline-infused @entity1 . Surgical denervation of left kidney reduced renal @entity2 (NE) to 58 and 14% of control levels at 1 and 7 days, respectively, after surgery. Increase in left renal resistance during posterior hypothalamus (PH) stimulation was only 70 +/- 28% (n = 5) compared with 289 +/- 69% (n = 6) in control animals. Response in opposite kidney was unchanged. Although 0.1 mg @entity4 ir caused considerable reduction of NE levels in both kidneys, responses to PH stimulation were unchanged. @entity4 (1 mg) reduced NE levels in infused and control kidney and atria. Functional evidence for denervation was only obtained in the kidney infused with @entity4 . Responses of MAP and HR to ir @entity3 were unchanged 7 days after 1 mg @entity4 . The data suggest that ir @entity4 results in functional efferent sympathectomy without affecting afferent @entity0 .

title: Selective efferent chemical sympathectomy of XXXX kidneys.

answer: @entity1


abstract: UNASSIGNED: To investigate the effect of inhibin gene immunization on antibody production and reproductive performance in broiler breeder females, Partridge @entity0 hens aged 380  days were immunized with inhibin recombinant plasmid pcISI. One hundred and twenty hens were randomly assigned to four groups and treated intramuscularly with 25, 75, or 125   g/300- L inhibin recombinant plasmid pcISI (T1   T3) or 300- L saline as control (C), respectively. Booster immunization was given with the same dosage 20  days later. Blood and egg samples were collected to detect the antibody against inhibin by enzyme-linked immunosorbent assay and to evaluate egg performance. The ovaries were collected to classify the follicles and detect the @entity1 ( @entity1 ) messenger RNA (mRNA) expression by reverse transcription-PCR. The results showed that immunization against pcISI could elicit antibody against inhibin in both plasma and egg yolk compared with the control (P  <  0.05), whereas booster immunization did not increase the antibody level in plasma. Vaccination promoted egg lay during the first 30  days after primary vaccination (P  <  0.05) with no effect on egg quality and hatching rate. Immunization increased the amounts of dominant, small yellow and large white follicles in the ovary (P  <  0.05). Reverse transcription-PCR results showed that immunization increased the @entity1 mRNA in the large white follicles, whereas decreased the @entity1 mRNA in the small yellow follicles (P  <  0.05). In conclusion, inhibin vaccine pcISI can stimulate the production of antibody against inhibin as well as the follicle development and egg laying performance in Partridge @entity0 hens, which provides a good foundation for the application of inhibin DNA vaccine in avian production.

title: Effect of inhibin gene immunization on antibody production and reproductive performance in Partridge XXXX hens.

answer: @entity0


abstract: BACKGROUND: Transcatheter @entity4 (TAVI) is a less invasive technique for the treatment of severe @entity1 in high-risk @entity0 . Occurrence of conduction disturbances requiring permanent pacemaker (PPM) implantation after TAVI is frequently observed. METHODS: The retrospective analysis comprised 153 @entity0 (96 @entity0 , aged from 65 to 97 years) who underwent TAVI due to high-grade @entity1 . The aim was to evaluate the incidence of high-grade atrioventricular (AV) block after TAVI and the percentage of ventricular pacing and pacemaker (PM)-dependency at the first follow-up 6-8 weeks after implantation. RESULTS: Out of the 153 @entity0 (age 81        6 years) who underwent TAVI, 144 (94   %) had a transfemoral and 9 (6   %) @entity0 a transapical approach. A PPM was implanted in 31 (20   %) @entity0 , 24 (16   %) were implanted with the Medtronic CoreValve   and 7 (5   %) with the Edwards Sapien   valve (p   =   n.s.). Complete @entity2 was the indication in 21 @entity0 (68   %), second-degree @entity2 in 1 @entity0 (3   %), slow @entity5 in 3 @entity0 (10   %), new @entity3 ( @entity3 ) plus sustained @entity6 ( @entity6 ) in 1 @entity0 (3   %), @entity7 in 2 @entity0 (7   %), whereas in 3 @entity0 (10   %) a PPM was inserted for safety reasons because of new @entity3 and first-grade @entity2 . All of the nine @entity0 (6   %) with a preexisting bundle @entity8 developed total @entity2 after TAVI. At follow-up PM-dependency (intrinsic rhythm <   30  bpm) occurred in 11/30 @entity0 (37   %), whereas an intrinsic rhythm >   50  bpm was seen in 17 @entity0 (57   %). At nominal device programming the percentage of ventricular stimulation (VP) during the short-term observation period was 60        44   % in dual-chamber devices (N   =   18), and 70        36   % in single-chamber PPM (N   =   5). CONCLUSION: The PPM implantation rate of about 20   % after TAVI is comparable to previously published data. The need for permanent pacing is linked to the valve type and preexistence of a @entity3 . At short-term more than half of the @entity0 implanted with a device were not strictly PM-dependent, but presented an underlying intrinsic rhythm, indicating that temporary AV conduction disturbances may recover over time. This might justify a more conservative approach in some @entity0 under watchful waiting. From another point of view, ventricular pacing at a regular or sensor-modulated rate may provide rhythm stability and chronotropy during the short-term period post-TAVI.

title: Short-term pacemaker dependency after transcatheter XXXX .

answer: @entity4


abstract: @entity0 pancreatic @entity4 (hpGRF1-44) was given intravenously as a 100 micrograms bolus to 20 @entity0 with active @entity2 . The GH-responses were variable, ranging from an increase of 8 to 2813% from the basal level (mean +/- SE, 428 +/- 136%). Sixteen GRF-responders (delta% greater than or equal to 100%) were arbitrarily distinguished from four GRF non-responders, whose GH-levels increased less than 100% from basal level after GRF-administration. The outcome of the GRF-test did not correlate with the results of other dynamic tests of GH-secretion in @entity2 (oral @entity1 tolerance test, insulin hypoglycaemia, TRH-, LHRH-, @entity3 -stimulation). In 10 @entity0 who had not been treated before, the GH-increments after GRF were higher than those in seven @entity0 who had previously been subjected to transsphenoidal surgery, though they still had clinically and biochemically active @entity2 . Ten acromegalics, who were tested with GRF, were later treated surgically by the transsphenoidal route and were reevaluated with GRF-stimulation 2 months after surgery. Eight @entity0 appeared clinically cured of whom four had complete normalization and four had significantly lower basal and conventionally stimulated GH-levels postoperatively. These @entity0 also had normal postoperative GH-responses to GRF, which had been significantly higher before surgery compared with normal controls. It is concluded that the GRF-test in @entity2 does not help in establishing the diagnosis. The normalization of the GH-response to GRF after transsphenoidal surgery seems to represent additional evidence for normalization of GH-secretion, though the latter is not proven by the normal outcome of this test.

title: XXXX -test in @entity2 : comparison with other dynamic tests.

answer: @entity4


abstract: @entity0 pancreatic @entity4 (hpGRF1-44) was given intravenously as a 100 micrograms bolus to 20 @entity0 with active @entity2 . The GH-responses were variable, ranging from an increase of 8 to 2813% from the basal level (mean +/- SE, 428 +/- 136%). Sixteen GRF-responders (delta% greater than or equal to 100%) were arbitrarily distinguished from four GRF non-responders, whose GH-levels increased less than 100% from basal level after GRF-administration. The outcome of the GRF-test did not correlate with the results of other dynamic tests of GH-secretion in @entity2 (oral @entity1 tolerance test, insulin hypoglycaemia, TRH-, LHRH-, @entity3 -stimulation). In 10 @entity0 who had not been treated before, the GH-increments after GRF were higher than those in seven @entity0 who had previously been subjected to transsphenoidal surgery, though they still had clinically and biochemically active @entity2 . Ten acromegalics, who were tested with GRF, were later treated surgically by the transsphenoidal route and were reevaluated with GRF-stimulation 2 months after surgery. Eight @entity0 appeared clinically cured of whom four had complete normalization and four had significantly lower basal and conventionally stimulated GH-levels postoperatively. These @entity0 also had normal postoperative GH-responses to GRF, which had been significantly higher before surgery compared with normal controls. It is concluded that the GRF-test in @entity2 does not help in establishing the diagnosis. The normalization of the GH-response to GRF after transsphenoidal surgery seems to represent additional evidence for normalization of GH-secretion, though the latter is not proven by the normal outcome of this test.

title: @entity4 -test in XXXX : comparison with other dynamic tests.

answer: @entity2


abstract: OBJECTIVE: To evaluate surgical outcomes for @entity2 of the temporal bone. STUDY DESIGN: Retrospective study. SETTING: Eye and ENT Hospital. METHODS: Seventy-two @entity0 with @entity2 of the temporal bone were analyzed for survival. The @entity0 were staged according to the modified Pittsburgh staging system. Five @entity0 with T1 @entity1 underwent local resection (LR), and 10 @entity0 with T1 @entity1 underwent lateral temporal bone resection (LTBR). Two @entity0 with @entity1 underwent LR, and 1 @entity0 with T2 @entity1 underwent LTBR. One @entity0 with T3 @entity1 underwent LR, 8 @entity0 with @entity1 underwent LTBR, and 10 @entity0 with @entity1 underwent subtotal temporal bone resection (STBR). Ten @entity0 with @entity1 underwent LTBR, and 25 @entity0 with @entity1 underwent STBR. RESULTS: Of all @entity0 that underwent surgery, 18 died of their disease during the follow-up time. The 5-year survival rates of @entity0 with T stages 1 through 4 were 100%, 67%, 21%, and 14%, respectively. There was no statistically significant difference in 5-year survival rate between T3 and T4 using the log-rank test (p > 0.05). The 5-year survival rates after LTBR and STBR for T3 were 26% and 16% (p > 0.05), respectively, and those for T4 were 17% and 11% (p > 0.05), respectively. CONCLUSION: An en bloc resection is favored in an effort to produce negative surgical margins for @entity2 of the temporal bone. Adjunctive radiotherapy is used for advanced lesions.

title: Survival outcomes in surgical treatment of 72 cases of XXXX of the temporal bone.

answer: @entity2


abstract: An experimental model was used which includes intragastric instillation of 80 mM @entity7 and 0.6 ml bile/kg followed by intravenous infusion of live @entity3 in @entity2 for up to three hours. This procedure regularly induces @entity6 . Mucosal blood flow was measured by microspheres before, early, and late in @entity0 . Total gastric blood flow was recorded electromagnetically. Mucosal regeneration capacity as reflected by the RNA/DNA ratio was measured. @entity1 (a PGE1 analogue) was infused iv (5 micrograms/kg X h) or given locally in the stomach (10 micrograms/kg) before bacteriemia. @entity1 did not influence the haemodynamic response to bacteria. The @entity5 was assessed either as an index representative for the entire corpus-fundus region or as the number of areas with intact surface epithelium within the series. @entity1 iv protected the mucosa from @entity4 compared with untreated septic controls while @entity1 intragastrically significantly reduced the number of damaged areas only. Topical @entity1 increased total @entity5 flows early in @entity0 compared to iv or no pretreatment while no difference was seen during late @entity0 . The protective effect of @entity1 was thus not dependent on increased gastric mucosal blood flow. Nor was it mediated through effects on mucosal nucleic acid concentrations or ratio.

title: Gastric mucosal damage in XXXX --effects of pretreatment with a synthetic prostaglandin E1 analogue.

answer: @entity0


abstract: @entity1 or @entity1 is a @entity2 coordination compound showing clinically useful antitumor activity, but the major dose-limiting factor is a dose-dependent cumulative nephrotoxicity. At the electron microscopic level, @entity2 has been localized in the nucleus, microsomes and cytoplasm of cells of the kidney and liver in @entity0 . This report confirms the subcellular localization of @entity2 and adds one more site of @entity2 accumulation, the microbody, based on results obtained with an energy-dispersive X-ray microanalyzer (EDX). After daily administration of @entity1 (0.5 mg/ml/kg body weight) successively for 5 weeks, accumulated @entity2 was detected in microbodies of hepatocytes and epithelial cells of proximal convoluted tubules of the @entity0 . The major site of metal deposition in the kidney was the matrix of many microbodies in the epithelial cells of proximal convoluted tubules. EDX revealed the presence of @entity2 in those metallic deposits. The matrix of the nucleus also had metallic deposits but they were rather diffuse and @entity2 could not readily be detected on individual grains in the nucleus. In the liver, major damage was concentrated in hepatocytes, and other types of cells such as Kupffer cells, Ito cells and endothelial cells of capillaries were less affected. Metallic fine grains were localized in the cisterna of smooth-surfaced endoplasmic reticulum and in the matrix of microbodies. The nucleus of hepatocytes had few, if any, metallic precipitates. A specific type of metallic deposition was round aggregations of dense tubules in which @entity2 was detected by EDX. There was no evidence of @entity2 precipitation in mitochondria or Golgi complex. These findings suggest that the microbody may play an important role in degradation of the @entity2 complex both in hepatocytes and epithelial cells of proximal convoluted tubules.

title: X-ray microanalysis and ultrastructural localization of XXXX in liver and kidney of the @entity0 .

answer: @entity1


abstract: @entity1 or @entity1 is a @entity2 coordination compound showing clinically useful antitumor activity, but the major dose-limiting factor is a dose-dependent cumulative nephrotoxicity. At the electron microscopic level, @entity2 has been localized in the nucleus, microsomes and cytoplasm of cells of the kidney and liver in @entity0 . This report confirms the subcellular localization of @entity2 and adds one more site of @entity2 accumulation, the microbody, based on results obtained with an energy-dispersive X-ray microanalyzer (EDX). After daily administration of @entity1 (0.5 mg/ml/kg body weight) successively for 5 weeks, accumulated @entity2 was detected in microbodies of hepatocytes and epithelial cells of proximal convoluted tubules of the @entity0 . The major site of metal deposition in the kidney was the matrix of many microbodies in the epithelial cells of proximal convoluted tubules. EDX revealed the presence of @entity2 in those metallic deposits. The matrix of the nucleus also had metallic deposits but they were rather diffuse and @entity2 could not readily be detected on individual grains in the nucleus. In the liver, major damage was concentrated in hepatocytes, and other types of cells such as Kupffer cells, Ito cells and endothelial cells of capillaries were less affected. Metallic fine grains were localized in the cisterna of smooth-surfaced endoplasmic reticulum and in the matrix of microbodies. The nucleus of hepatocytes had few, if any, metallic precipitates. A specific type of metallic deposition was round aggregations of dense tubules in which @entity2 was detected by EDX. There was no evidence of @entity2 precipitation in mitochondria or Golgi complex. These findings suggest that the microbody may play an important role in degradation of the @entity2 complex both in hepatocytes and epithelial cells of proximal convoluted tubules.

title: X-ray microanalysis and ultrastructural localization of @entity1 in liver and kidney of the XXXX .

answer: @entity0


abstract: Previously, we have derived @entity1 hybridomas producing monoclonal antibodies against DNA methyltransferase from @entity0 placenta (Kaul, S., Pfeifer, G. P., and Drahovsky, D. (1984) Eur. J. Cell Biol. 34, 330-335). One of these monoclonal antibodies, M2B10, which undergoes immune complex formation also with DNA methyltransferase from @entity1 @entity1 @entity7 cells, was used for the immunoaffinity purification of @entity1 and @entity0 DNA methyltransferases. In @entity4 - @entity3 gels and in immunoblotting studies, the immunoaffinity-purified @entity1 DNA methyltransferase revealed 5-6 polypeptides of molecular masses 150-190 kDa. The immunoaffinity-purified @entity0 placental DNA methyltransferase was characterized by a polypeptide of 158 kDa, presumably representing the native enzyme molecule and by polypeptides of 105-108 kDa and 50-68 kDa, probably generated by a limited proteolysis of the native enzyme molecule. The immunoaffinity-purified DNA methyltransferases preferred hemimethylated DNA substrates over unmethylated ones, and among all unmethylated substrates tested, @entity8 .(dG-dC)] had the highest @entity6 -accepting activity. DNA polymers of at least 90 base pairs in length were required for the binding reaction of the immunoaffinity-purified @entity0 DNA methyltransferase, and this initial binding was apparently independent of the @entity2 composition of the DNA polymer and of the presence of @entity5 .

title: Purification and characterization of XXXX DNA methyltransferases by use of monoclonal antibodies.

answer: @entity0


abstract: BACKGROUND/AIMS: Autologous stem cell transplantation (ASCT) has become the treatment of choice for @entity0 with @entity6 ( @entity6 ). Studies have shown that maintenance treatment with interferon-alpha is associated with improved survival rates following ASCT. However, despite these recent advances in regimes, relapses are inevitable; thus, the prediction of relapse following ASCT requires assessment. METHODS: We retrospectively analyzed 39 @entity0 who received ASCT between 2003 and 2008. All @entity0 received chemotherapy with @entity7 , @entity4 , and @entity3 (VAD), and ASCT was performed following high-dose melphalan conditioning therapy. We evaluated the influence of the post-transplant day +14 ( @entity1 ) bone marrow plasma cell percent (BMPCp) (>=  2 vs. < 2%), @entity2 ( @entity2 ) stage (II vs. III), response after 3 cycles of VAD therapy (complete response [CR] vs. non-CR), deletion of chromosome 13q (del[13q]) (presence of the abnormality vs. absence), and BMPCp at diagnosis (>=  50 vs. < 50%) on progression-free survival (PFS) and @entity5 ( @entity5 ). RESULTS: During the median follow-up of 28.0 months, the median PFS and @entity5 were 29.1 and 42.1 months, respectively. By univariate analysis, @entity2 stage III at diagnosis, BMPCp >=  50% at diagnosis, CR after 3 cycles of VAD therapy, del (13q) by fluorescence in situ hybridization, and BMPCp >=  2% at post-transplant D+14 were correlated with PFS and @entity5 . A multivariate analysis revealed that a post-transplant D+14 BMPCp >=  2% (PFS, hazard ratio [HR] = 4.426, p = 0.008; @entity5 , HR = 3.545, p = 0.038) and CR after 3 cycles of VAD therapy (PFS, HR = 0.072, p = 0.014; @entity5 , HR = 0.055, p = 0.015) were independent prognostic parameters. CONCLUSIONS: Post-transplant D+14 BMPCp is a useful parameter for predicting the outcome for @entity0 with @entity6 receiving ASCT.

title: Predictive value of post-transplant bone marrow plasma cell percent in XXXX @entity0 undergone autologous transplantation.

answer: @entity6


abstract: BACKGROUND/AIMS: Autologous stem cell transplantation (ASCT) has become the treatment of choice for @entity0 with @entity6 ( @entity6 ). Studies have shown that maintenance treatment with interferon-alpha is associated with improved survival rates following ASCT. However, despite these recent advances in regimes, relapses are inevitable; thus, the prediction of relapse following ASCT requires assessment. METHODS: We retrospectively analyzed 39 @entity0 who received ASCT between 2003 and 2008. All @entity0 received chemotherapy with @entity7 , @entity4 , and @entity3 (VAD), and ASCT was performed following high-dose melphalan conditioning therapy. We evaluated the influence of the post-transplant day +14 ( @entity1 ) bone marrow plasma cell percent (BMPCp) (>=  2 vs. < 2%), @entity2 ( @entity2 ) stage (II vs. III), response after 3 cycles of VAD therapy (complete response [CR] vs. non-CR), deletion of chromosome 13q (del[13q]) (presence of the abnormality vs. absence), and BMPCp at diagnosis (>=  50 vs. < 50%) on progression-free survival (PFS) and @entity5 ( @entity5 ). RESULTS: During the median follow-up of 28.0 months, the median PFS and @entity5 were 29.1 and 42.1 months, respectively. By univariate analysis, @entity2 stage III at diagnosis, BMPCp >=  50% at diagnosis, CR after 3 cycles of VAD therapy, del (13q) by fluorescence in situ hybridization, and BMPCp >=  2% at post-transplant D+14 were correlated with PFS and @entity5 . A multivariate analysis revealed that a post-transplant D+14 BMPCp >=  2% (PFS, hazard ratio [HR] = 4.426, p = 0.008; @entity5 , HR = 3.545, p = 0.038) and CR after 3 cycles of VAD therapy (PFS, HR = 0.072, p = 0.014; @entity5 , HR = 0.055, p = 0.015) were independent prognostic parameters. CONCLUSIONS: Post-transplant D+14 BMPCp is a useful parameter for predicting the outcome for @entity0 with @entity6 receiving ASCT.

title: Predictive value of post-transplant bone marrow plasma cell percent in @entity6 XXXX undergone autologous transplantation.

answer: @entity0


abstract: BACKGROUND/AIMS: Limited options remain for @entity0 with metastatic @entity1 ( @entity1 ) after failure of standard systemic chemotherapy. Readministration of chemotherapeutic agents by hepatic arterial infusion (HAI) has the rationale of providing higher concentrations of chemotherapeutic agents to hepatic metastases. The present study was conducted to evaluate the efficacy and safety of HAI of @entity6 with @entity8 (HAI 5-FU/LV) for @entity0 with liver metastases from @entity1 . METHODS: Fourteen @entity0 with liver metastases from @entity1 who received HAI 5-FU/LV after failure of systemic chemotherapy containing @entity6 and @entity8 were identified and their medical records were reviewed. RESULTS: Of 10 @entity0 evaluable for response, one partial response, six stable disease, and three progressive disease were reported. Additionally, the overall response and disease control rates were 7% and 50%, respectively. The median time to progression was 4.3 months (range, 2.9 to 5.6), to hepatic progression was 5.8 months (range, 4.7 to 6.9), and to extrahepatic progression was 5.8 months (range, 2.3 to 9.2). No grade 3/4 hematologic @entity2 occurred and one case of @entity4 and two cases of @entity7 were the only grade 3 nonhematologic @entity2 . Catheter-related complications occurred in three @entity0 : one @entity5 , one @entity3 , and one displacement. CONCLUSIONS: HAI 5-FU/LV was well tolerated and showed modest efficacy for @entity0 with liver metastases from refractory @entity1 . Readministration of previously used chemotherapeutic agents via the hepatic artery could be an effective salvage option and warrants further investigation in a prospective trial.

title: Efficacy and safety of hepatic arterial infusion of @entity6 with XXXX as salvage treatment for refractory liver metastases from @entity1 .

answer: @entity8


abstract: BACKGROUND/AIMS: Limited options remain for @entity0 with metastatic @entity1 ( @entity1 ) after failure of standard systemic chemotherapy. Readministration of chemotherapeutic agents by hepatic arterial infusion (HAI) has the rationale of providing higher concentrations of chemotherapeutic agents to hepatic metastases. The present study was conducted to evaluate the efficacy and safety of HAI of @entity6 with @entity8 (HAI 5-FU/LV) for @entity0 with liver metastases from @entity1 . METHODS: Fourteen @entity0 with liver metastases from @entity1 who received HAI 5-FU/LV after failure of systemic chemotherapy containing @entity6 and @entity8 were identified and their medical records were reviewed. RESULTS: Of 10 @entity0 evaluable for response, one partial response, six stable disease, and three progressive disease were reported. Additionally, the overall response and disease control rates were 7% and 50%, respectively. The median time to progression was 4.3 months (range, 2.9 to 5.6), to hepatic progression was 5.8 months (range, 4.7 to 6.9), and to extrahepatic progression was 5.8 months (range, 2.3 to 9.2). No grade 3/4 hematologic @entity2 occurred and one case of @entity4 and two cases of @entity7 were the only grade 3 nonhematologic @entity2 . Catheter-related complications occurred in three @entity0 : one @entity5 , one @entity3 , and one displacement. CONCLUSIONS: HAI 5-FU/LV was well tolerated and showed modest efficacy for @entity0 with liver metastases from refractory @entity1 . Readministration of previously used chemotherapeutic agents via the hepatic artery could be an effective salvage option and warrants further investigation in a prospective trial.

title: Efficacy and safety of hepatic arterial infusion of @entity6 with @entity8 as salvage treatment for refractory liver metastases from XXXX .

answer: @entity1


abstract: BACKGROUND/AIMS: Limited options remain for @entity0 with metastatic @entity1 ( @entity1 ) after failure of standard systemic chemotherapy. Readministration of chemotherapeutic agents by hepatic arterial infusion (HAI) has the rationale of providing higher concentrations of chemotherapeutic agents to hepatic metastases. The present study was conducted to evaluate the efficacy and safety of HAI of @entity6 with @entity8 (HAI 5-FU/LV) for @entity0 with liver metastases from @entity1 . METHODS: Fourteen @entity0 with liver metastases from @entity1 who received HAI 5-FU/LV after failure of systemic chemotherapy containing @entity6 and @entity8 were identified and their medical records were reviewed. RESULTS: Of 10 @entity0 evaluable for response, one partial response, six stable disease, and three progressive disease were reported. Additionally, the overall response and disease control rates were 7% and 50%, respectively. The median time to progression was 4.3 months (range, 2.9 to 5.6), to hepatic progression was 5.8 months (range, 4.7 to 6.9), and to extrahepatic progression was 5.8 months (range, 2.3 to 9.2). No grade 3/4 hematologic @entity2 occurred and one case of @entity4 and two cases of @entity7 were the only grade 3 nonhematologic @entity2 . Catheter-related complications occurred in three @entity0 : one @entity5 , one @entity3 , and one displacement. CONCLUSIONS: HAI 5-FU/LV was well tolerated and showed modest efficacy for @entity0 with liver metastases from refractory @entity1 . Readministration of previously used chemotherapeutic agents via the hepatic artery could be an effective salvage option and warrants further investigation in a prospective trial.

title: Efficacy and safety of hepatic arterial infusion of XXXX with @entity8 as salvage treatment for refractory liver metastases from @entity1 .

answer: @entity6


abstract: @entity0 are a feature of @entity1 ( @entity1 ). Unlike motor symptoms that are clearly improved by dopaminergic therapy, the effect of @entity2 replacement on cognition seems paradoxical. Some cognitive functions are improved whereas others are unaltered or even hindered. Our aim was to understand the effect of @entity2 replacement therapy on various aspects of cognition. Whereas dorsal striatum receives @entity2 input from the substantia nigra (SN), ventral striatum is innervated by @entity2 -producing cells in the ventral tegmental area (VTA). In @entity1 , degeneration of SN is substantially greater than cell loss in VTA and hence @entity2 -deficiency is significantly greater in dorsal compared to ventral striatum. We suggest that @entity2 supplementation improves functions mediated by dorsal striatum and impairs, or heightens to a pathological degree, operations ascribed to ventral striatum. We consider the extant literature in light of this principle. We also survey the effect of @entity2 replacement on functional neuroimaging in @entity1 relating the findings to this framework. This paper highlights the fact that currently, titration of therapy in @entity1 is geared to optimizing dorsal striatum-mediated motor symptoms, at the expense of ventral striatum operations. Increased awareness of contrasting effects of @entity2 replacement on dorsal versus ventral striatum functions will lead clinicians to survey a broader range of symptoms in determining optimal therapy, taking into account both those aspects of cognition that will be helped versus those that will be hindered by dopaminergic treatment.

title: Differential effects of dopaminergic therapies on dorsal and ventral striatum in XXXX : implications for cognitive function.

answer: @entity1


abstract: BACKGROUND: Differences in spontaneous and drug-induced baroreflex sensitivity ( @entity4 ) have been attributed to its different operating ranges. The current study attempted to compare @entity4 estimates during cardiovascular steady-state and pharmacologically stimulation using an innovative algorithm for dynamic determination of baroreflex gain. METHODOLOGY/PRINCIPAL FINDINGS: Forty-five volunteers underwent the modified Oxford maneuver in supine and 60   tilted position with blood pressure and heart rate being continuously recorded. Drug-induced @entity4 -estimates were calculated from data obtained by bolus injections of @entity1 and @entity3 . Spontaneous indices were derived from data obtained during rest (stationary) and under pharmacological stimulation (non-stationary) using the algorithm of @entity2 ( @entity2 ). Spontaneous and drug-induced @entity4 values were significantly correlated and display directionally similar changes under different situations. Using the Bland-Altman method, systematic differences between spontaneous and drug-induced estimates were found and revealed that the discrepancy can be as large as the gain itself. Fixed bias was not evident with ordinary least products regression. The correlation and agreement between the estimates increased significantly when @entity4 was calculated by @entity2 in non-stationary mode during the drug injection period. @entity2 - @entity4 significantly increased during @entity3 and decreased under @entity1 . CONCLUSIONS/SIGNIFICANCE: The @entity2 analysis provides a reliable, non-invasive assessment of @entity0 @entity4 not only under static steady state conditions, but also during pharmacological perturbation of the cardiovascular system.

title: Determination of baroreflex sensitivity during the modified Oxford maneuver by XXXX .

answer: @entity2


abstract: Various types of exercise alter the population of circulating peripheral blood mononuclear cells (PBMCs) and change their transcriptional output. This work examines changes in PBMC populations and transcription in response to resistance exercise training (RET), and identify key transcriptional changes in PBMCs that may play a role in altering peripheral tissues in response to RET. Ten resistance-trained @entity0 (20-24 years), performed an acute bout of RET for ~30 min following a 12 h fast. Venous blood was sampled at rest, immediately following exercise, and at 2 h post-exercise and analyzed for total and differential leukocytes and global gene expression using Affymetrix Genechips. Results showed elevated leukocytes, monocytes, lymphocytes, and @entity3 values immediately post-exercise (P < 0.05) over baseline. At 2 h post-exercise, leukocytes, and granulocytes remained elevated (P < 0.05), whereas lymphocytes were lower than (P < 0.05) baseline values. Initial microarray results showed the greatest transcriptional changes in pathways related to immune response, @entity1 , and cellular communication. The change in PBMC population (2 h time point) correlated with a dramatic decrease in the expression of @entity7 , and @entity9 , markers of lymphocyte populations. At the 2 h recovery time point upregulation of @entity4 , @entity5 , @entity6 , and @entity8 suggest an induction in @entity2 and repair during this time frame. These results demonstrate that an acute bout of RET disrupts cellular homeostasis, induces a transient redistribution of certain leukocytes, and results in transcriptional changes in PBMCs translating into systemic changes in response to RET.

title: Changes in transcriptional output of XXXX peripheral blood mononuclear cells following resistance exercise.

answer: @entity0


abstract: Altered levels of matrix metalloproteinases (MMPs) may reflect relevant pathogenetic mechanisms of disease conditions. The objective of this study was to compare the plasma levels of MMPs and tissue inhibitors of MMPs (TIMPs) in @entity7 ( @entity7 ) @entity0 with those found in healthy ovulatory controls and to examine whether the levels of these biomarkers are associated with clinical and biochemical features of this syndrome. Sixty-five healthy ovulatory subjects (controls) and 80 @entity0 with @entity7 were include in this study. @entity3 , @entity8 , @entity4 , @entity6 , @entity5 concentrations were measured in plasma samples by gelatin zymography or enzyme-linked immunoassays. @entity3 , @entity8 , @entity4 , and @entity6 levels were similar in @entity7 @entity0 and in healthy controls (P > 0.05). @entity7 @entity0 had lower plasma @entity5 levels than healthy controls (P < 0.05). We found higher @entity3 / @entity5 and @entity4 / @entity6 ratios in @entity7 @entity0 than in healthy controls (all P < 0.05). @entity1 levels correlated positively with the @entity4 / @entity6 ratio and negatively with @entity5 levels (r = 0.26, P < 0.01 and r = -0.21, P = 0.02, respectively). In addition, only @entity1 was an independent predictor of @entity5 levels (estimate = -0.35, P = 0.04) and the @entity4 / @entity6 ratio (estimate = 0.01, P = 0.04). We found evidence indicating that the balance between MMPs and TIMPs in @entity0 with @entity7 is altered, probably due to @entity2 excess found in these @entity0 .

title: Imbalanced circulating matrix metalloproteinases in XXXX .

answer: @entity7


abstract: OBJECTIVE OF STUDY: To evaluate the efficacy of radiofrequency ablation (RFA) of @entity4 ( @entity4 ) using non-contact electro-anatomic mapping in @entity0 with @entity5 @entity1 / @entity2 ( @entity5 /C). METHODS: Fifteen consecutive @entity0 (44    15 years) with @entity5 /C and symptomatic VTs were studied. Eight @entity0 had @entity3 . Two @entity0 had recurrent @entity4 while on AICD; in three @entity0 , RFA was done prior to AICD implantation, and ten @entity0 refused AICD. After obtaining activation maps, first, the clinical @entity4 was targeted, and then, other VTs were sought. RESULTS: Twenty-five inducible VTs were mapped, and 22 of them were successfully ablated. In 13 out of 15 @entity0 , all the clinical and inducible VTs were ablated. In two @entity0 , non-clinical inducible VTs could not be ablated. At 25    16 months (2-52 months), all @entity0 remained asymptomatic. Antiarrhythmic medications were discontinued after 6 months. Two @entity0 had recurrence of non-clinical @entity4 on follow-up. There were no episodes of asymptomatic @entity4 recorded in five @entity0 with AICD. CONCLUSION: A majority of induced @entity4 in @entity0 with @entity5 /C can be successfully mapped and ablated using the non-contact Ensite Array Mapping system with good long-term @entity4 -free outcome. Ablation can be a useful adjunct to AICD implantation in such @entity0 .

title: Radiofrequency catheter ablation of @entity4 in @entity5 XXXX / @entity2 using non-contact electroanatomical mapping: single-center experience with follow-up up to median of 30 months.

answer: @entity1


abstract: OBJECTIVE OF STUDY: To evaluate the efficacy of radiofrequency ablation (RFA) of @entity4 ( @entity4 ) using non-contact electro-anatomic mapping in @entity0 with @entity5 @entity1 / @entity2 ( @entity5 /C). METHODS: Fifteen consecutive @entity0 (44    15 years) with @entity5 /C and symptomatic VTs were studied. Eight @entity0 had @entity3 . Two @entity0 had recurrent @entity4 while on AICD; in three @entity0 , RFA was done prior to AICD implantation, and ten @entity0 refused AICD. After obtaining activation maps, first, the clinical @entity4 was targeted, and then, other VTs were sought. RESULTS: Twenty-five inducible VTs were mapped, and 22 of them were successfully ablated. In 13 out of 15 @entity0 , all the clinical and inducible VTs were ablated. In two @entity0 , non-clinical inducible VTs could not be ablated. At 25    16 months (2-52 months), all @entity0 remained asymptomatic. Antiarrhythmic medications were discontinued after 6 months. Two @entity0 had recurrence of non-clinical @entity4 on follow-up. There were no episodes of asymptomatic @entity4 recorded in five @entity0 with AICD. CONCLUSION: A majority of induced @entity4 in @entity0 with @entity5 /C can be successfully mapped and ablated using the non-contact Ensite Array Mapping system with good long-term @entity4 -free outcome. Ablation can be a useful adjunct to AICD implantation in such @entity0 .

title: Radiofrequency catheter ablation of @entity4 in @entity5 @entity1 / XXXX using non-contact electroanatomical mapping: single-center experience with follow-up up to median of 30 months.

answer: @entity2


abstract: OBJECTIVE OF STUDY: To evaluate the efficacy of radiofrequency ablation (RFA) of @entity4 ( @entity4 ) using non-contact electro-anatomic mapping in @entity0 with @entity5 @entity1 / @entity2 ( @entity5 /C). METHODS: Fifteen consecutive @entity0 (44    15 years) with @entity5 /C and symptomatic VTs were studied. Eight @entity0 had @entity3 . Two @entity0 had recurrent @entity4 while on AICD; in three @entity0 , RFA was done prior to AICD implantation, and ten @entity0 refused AICD. After obtaining activation maps, first, the clinical @entity4 was targeted, and then, other VTs were sought. RESULTS: Twenty-five inducible VTs were mapped, and 22 of them were successfully ablated. In 13 out of 15 @entity0 , all the clinical and inducible VTs were ablated. In two @entity0 , non-clinical inducible VTs could not be ablated. At 25    16 months (2-52 months), all @entity0 remained asymptomatic. Antiarrhythmic medications were discontinued after 6 months. Two @entity0 had recurrence of non-clinical @entity4 on follow-up. There were no episodes of asymptomatic @entity4 recorded in five @entity0 with AICD. CONCLUSION: A majority of induced @entity4 in @entity0 with @entity5 /C can be successfully mapped and ablated using the non-contact Ensite Array Mapping system with good long-term @entity4 -free outcome. Ablation can be a useful adjunct to AICD implantation in such @entity0 .

title: Radiofrequency catheter ablation of XXXX in @entity5 @entity1 / @entity2 using non-contact electroanatomical mapping: single-center experience with follow-up up to median of 30 months.

answer: @entity4


abstract: OBJECTIVE OF STUDY: To evaluate the efficacy of radiofrequency ablation (RFA) of @entity4 ( @entity4 ) using non-contact electro-anatomic mapping in @entity0 with @entity5 @entity1 / @entity2 ( @entity5 /C). METHODS: Fifteen consecutive @entity0 (44    15 years) with @entity5 /C and symptomatic VTs were studied. Eight @entity0 had @entity3 . Two @entity0 had recurrent @entity4 while on AICD; in three @entity0 , RFA was done prior to AICD implantation, and ten @entity0 refused AICD. After obtaining activation maps, first, the clinical @entity4 was targeted, and then, other VTs were sought. RESULTS: Twenty-five inducible VTs were mapped, and 22 of them were successfully ablated. In 13 out of 15 @entity0 , all the clinical and inducible VTs were ablated. In two @entity0 , non-clinical inducible VTs could not be ablated. At 25    16 months (2-52 months), all @entity0 remained asymptomatic. Antiarrhythmic medications were discontinued after 6 months. Two @entity0 had recurrence of non-clinical @entity4 on follow-up. There were no episodes of asymptomatic @entity4 recorded in five @entity0 with AICD. CONCLUSION: A majority of induced @entity4 in @entity0 with @entity5 /C can be successfully mapped and ablated using the non-contact Ensite Array Mapping system with good long-term @entity4 -free outcome. Ablation can be a useful adjunct to AICD implantation in such @entity0 .

title: Radiofrequency catheter ablation of @entity4 in XXXX @entity1 / @entity2 using non-contact electroanatomical mapping: single-center experience with follow-up up to median of 30 months.

answer: @entity5


abstract: OBJECTIVE: To assess the effect of timing of presentation of cases with @entity3 on the outcome of surgical intervention. @entity0 AND METHODS: Between January 1986 and May 2010, 180 @entity0 with @entity3 were treated surgically in our center. To assess the effect of timing of presentation, @entity0 were classified into 2 groups: group I with early presentation ( <=24 hours) and group II with delayed presentation (>24 hours). All @entity0 were contacted by mail or phone and were re-evaluated. All @entity0 were reevaluated by questionnaire and local examination. @entity0 with @entity2 were evaluated by color Doppler ultrasonography. RESULTS: Group I included 149 @entity0 (82.8%) and group II included 31 (17.2%). In group I, @entity0 presented to the emergency department from 1-24 hours (mean, 11.8) after occurrence of the @entity3 . Although @entity0 in group II presented from 30 hours to 7 days (mean, 44.7 hours). Both groups were similar regarding etiology of injury, clinical presentation, surgical findings, and incidence of associated @entity1 . Mean follow-up period for group I was 105 months, and for group II it was 113 months. After such long-term follow up, 35 (19.4%) @entity0 had complications; however, there was no statistically significant difference between both groups. CONCLUSIONS: Cases of @entity3 with early or delayed presentation up to 7 days should be managed surgically. Both groups have comparable excellent outcome with no serious long-term complications.

title: Does timing of presentation of XXXX affect outcome of surgical intervention?

answer: @entity3


abstract: BACKGROUND AND PURPOSE: The aim of this study was to assess the clinical outcome of @entity0 treated with the Penumbra system (PS) for acute @entity2 . A retrospective, monocentric matched-pair analysis in comparison with @entity0 treated by intraarterial thrombolysis (IAT) with alteplase was designed for this purpose. METHODS: Twenty-two consecutive @entity0 , (mean age 62), with acute @entity2 and National Institutes of Health @entity1 Scale (NIHSS) scores >=  7 were treated with the PS. Twenty corresponding @entity0 could be identified, treated with IAT. Matches were sought for initial NIHSS score and target vessels. Thrombolysis in @entity3 (TIMI) grades, mortality rates, NIHSS upon discharge, and modified Rankin scores (mRs) at 90 days were compared. RESULTS: A total of 32 vessels in 20 @entity0 were treated in either arm of the study. Recanalization to TIMI 2/3 was successful in 25/32 (78%) of target vessels with the PS, and 17/32 (53%) of target vessels in the IAT group. Upon discharge, 2/20 @entity0 treated with PS and 7/20 @entity0 treated with IAT had a NIHSS score of 0 to 1 or an improvement greater or equal to 10-point on the NIHSS scale. All cause mortality at 90 days was 3/20 @entity0 treated with PS, and 2/20 @entity0 treated with IAT. Three out of twenty @entity0 treated with PS and 7/20 @entity0 treated with IAT had a mRS of  <= 2 at 90 days. CONCLUSION: The Penumbra system is effective in re-opening occluded major arteries. Our data seems to indicate that not all @entity0 benefit clinically from improved revascularization of occluded major arteries.

title: Mechanical thrombectomy with the Penumbra recanalization device in acute XXXX .

answer: @entity2


abstract: PURPOSE: We hypothesize that a failure to normalize a @entity0 's @entity2 on an automated euglycemia protocol signals an adverse response after @entity1 and that this response can identify @entity0 with an increased mortality. MATERIALS AND METHODS: There were 1246 ventilated, critically ill @entity1 @entity0 who were placed on an automated euglycemia. All @entity2 values collected both by laboratory serum measurements and by bedside arterial samples were included in the analysis. RESULTS: Forty six thousand two hundred eighteen data entries for @entity2 (mg/dL) were analyzed. Time to normalization, defined as the first value in the goal range of 80 to 110 mg/dL, was different between the 2 groups, survivors correcting significantly faster (396 vs 487 minutes; P = .003). Mortality in @entity0 who normalized (80-110 mg/dL) in the first 6 hours of admission was 13.6% vs 18.3% in @entity0 requiring greater than 6 hours (P = .02). @entity0 who never normalized also required significantly greater @entity3 doses despite there being no significant difference in demographic data between the 2 groups. CONCLUSIONS: A posttraumatic @entity0 's response to tight glycemic control revealed important prognostic information about the @entity0 ' physiologic status. @entity0 who failed to reach euglycemia in the first 6 hours of admission had an increased hospital mortality. The time to normalization is significantly longer in those @entity0 who died. @entity0 who did not correct rapidly required significantly higher @entity3 doses, suggesting @entity3 resistance.

title: Failure to achieve euglycemia despite aggressive @entity3 control signals abnormal physiologic response to XXXX .

answer: @entity1


abstract: PURPOSE: We hypothesize that a failure to normalize a @entity0 's @entity2 on an automated euglycemia protocol signals an adverse response after @entity1 and that this response can identify @entity0 with an increased mortality. MATERIALS AND METHODS: There were 1246 ventilated, critically ill @entity1 @entity0 who were placed on an automated euglycemia. All @entity2 values collected both by laboratory serum measurements and by bedside arterial samples were included in the analysis. RESULTS: Forty six thousand two hundred eighteen data entries for @entity2 (mg/dL) were analyzed. Time to normalization, defined as the first value in the goal range of 80 to 110 mg/dL, was different between the 2 groups, survivors correcting significantly faster (396 vs 487 minutes; P = .003). Mortality in @entity0 who normalized (80-110 mg/dL) in the first 6 hours of admission was 13.6% vs 18.3% in @entity0 requiring greater than 6 hours (P = .02). @entity0 who never normalized also required significantly greater @entity3 doses despite there being no significant difference in demographic data between the 2 groups. CONCLUSIONS: A posttraumatic @entity0 's response to tight glycemic control revealed important prognostic information about the @entity0 ' physiologic status. @entity0 who failed to reach euglycemia in the first 6 hours of admission had an increased hospital mortality. The time to normalization is significantly longer in those @entity0 who died. @entity0 who did not correct rapidly required significantly higher @entity3 doses, suggesting @entity3 resistance.

title: Failure to achieve euglycemia despite aggressive XXXX control signals abnormal physiologic response to @entity1 .

answer: @entity3